MOXIDECTIN INJECTIO

The contract solicitation SPE2DP-26-T-4485 seeks the procurement of 5,000 kits of Moxidectin Injection, a veterinary pharmaceutical intended for subcutaneous use in dogs 12 months of age and older. Each kit contains a 10 mL vial of Moxidectin microspheres at 10 mg/mL after constitution, a separate 8 mL vial of sterile vehicle, and one vent needle. The product must be stored unconstituted at or below 25°C (77°F) and protected from prolonged light exposure; after constitution, it remains stable for eight weeks when refrigerated at 2–8°C (36–46°F). The item has a 24-month non-extendable shelf life under Type I (Code M) requirements and is regulated by the FDA, necessitating referral for confirmation prior to award. The unit of issue is a kit (KT), and delivery is required FOB destination within 20 days of award, with no variance allowed in quantity. The product must be packaged and marked in strict compliance with Medical Marking Standard No. 1, which supersedes MIL-STD-129 for medical acquisitions, and packaging must adhere to MIL-STD-2073-1E. Palletization must follow DLA Packaging Requirements for Procurement (RP001). Delivery is to Fort Sam Houston, Texas, with shipments required via traceable means excluding parcel post. The contract includes multiple federal acquisition regulation clauses addressing contract type, small business representation, system for award management maintenance, prohibition on confidentiality agreements, safety issue notifications, subcontracts for commercial services, pricing adjustments, payment levies, contract modifications, safeguarding of covered contractor information systems, accelerated payments to small business subcontractors, and unenforceability of unauthorized obligations. Authorization and consent clauses utilize Alternates I and II. The solicitation mandates compliance with technical and quality requirements from the DLA Master List, including removal of government identification from non-accepted supplies and potential applicability of covered defense information protocols. While no formal evaluation factors or scoring weights are specified, the process appears to follow a Lowest Price Technically Acceptable model, with technical compliance and regulatory adherence being mandatory. Payment will be processed through Wide Area WorkFlow, and the contract is administered by the Department of Defense’s Medical Supply Chain PHARM FSA, with Shairy M. Cartagena as the pre-award point of contact.